After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is “not sure these data will be enough to move the needle.” Brill maintains a Neutral rating on Alkermes.
https://thefly.com/landingPageNews.php?id=2890407
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.